Skip to main content

Table 1 Clinical baseline characteristic and medication data

From: Biodegradable polymer drug-eluting stents versus second-generation drug-eluting stents in patients with and without diabetes mellitus: a single-center study

Characteristics

DM

P

No-DM

P

G2‑DES

N = 1862

BP‑DES

N = 421

G2‑DES

N = 4232

BP‑DES

N = 1151

Age (years)

59.0 ± 9.7

59.7 ± 9.7

0.814

57.5 ± 10.6

58.5 ± 10.4

0.241

Sex (male)

1411 (75.8)

314 (74.6)

0.607

3307 (78.1)

872 (75.8)

0.085

BMI (kg/m2)

26.3 ± 3.1

26.2 ± 3.1

0.595

25.8 ± 3.2

25.8 ± 3.1

0.754

LVEF (%)

62.7 ± 7.5

61.8 ± 7.9

0.207

63.1 ± 7.2

61.8 ± 7.9

0.262

Hypertension (n, %)

1284 (69.0)

314 (74.6)

0.023

2545 (60.1)

726 (63.1)

0.070

Hyperlipidemia (n, %)

1383 (74.3)

306 (72.7)

0.502

2754 (65.1)

717 (62.3)

0.080

Current smoker (n, %)

1014 (54.5)

240 (57.0)

0.342

2414 (57.0)

685 (59.5)

0.132

Family history (n, %)

486 (26.1)

102 (24.2)

0.427

1047 (24.7)

264 (22.9)

0.206

Stroke history (n, %)

231 (12.4)

60 (14.3)

0.305

369 (8.7)

118 (10.3)

0.108

PAD (n, %)

62 (3.3)

19 (4.5)

0.236

99 (2.3)

18 (1.6)

0.110

COPD (n, %)

43 (2.3)

10 (2.4)

0.935

98 (2.3)

26 (2.3)

0.158

OMI (n, %)

348 (18.7)

101 (24.0)

0.013

749 (17.7)

211 (18.3)

0.619

Previous PCI (n, %)

480 (25.8)

133 (31.6)

0.015

976 (23.1)

247 (21.5)

0.250

Previous CABG (n, %)

82 (4.4)

21 (5.0)

0.602

163 (3.9)

25 (2.2)

0.006

Serum creatinine (ml/min)

74.9 ± 16.7

76.9 ± 17.8

0.233

75.4 ± 15.3

76.2 ± 15.5

0.425

HbA1c (%)

7.8 ± 1.4

7.9 ± 1.4

0.772

6.1 ± 0.6

6.1 ± 0.6

0.744

Clinical presentation (n, %)

 Stable angia

796 (42.7)

175 (41.6)

0.658

1631 (38.5)

432 (37.5)

0.533

 NSTE-ACS

857 (46.0)

189 (44.9)

0.674

2026 (47.9)

534 (46.4)

0.373

 STEMI

209 (11.2)

57 (13.5)

0.181

574 (13.6)

185 (16.1)

0.030

Medication (cases, %)

 Aspirin

1841 (98.9)

419 (99.5)

0.289

4173 (98.6)

1140 (99.0)

0.244

 Clopidogrel

1840 (98.8)

416 (98.8)

> 0.999

4159 (98.3)

1138 (98.9)

0.153

 DAPT

1821 (97.8)

415 (98.6)

0.311

4104 (97.0)

1131 (98.3)

0.018

 GP IIIb/IIa inhibitors

206 (11.1)

62 (14.7)

0.035

500 (11.8)

217 (18.9)

< 0.001

 Statin

1774 (95.3)

406 (96.4)

0.299

4071 (96.2)

1104 (95.9)

0.663

 β‑blocker

1705 (91.6)

403 (95.7)

0.004

3782 (89.4)

1021 (88.7)

0.521

 Calcium antagonist

956 (51.3)

221 (52.5)

0.669

2002 (47.3)

518 (45.0)

0.165

 Nitrate

1807 (97.0)

414 (98.3)

0.141

4130 (97.6)

1127 (97.9)

0.518

 PPI

341 (18.3)

79 (18.8)

0.829

836 (19.8)

266 (23.1)

0.012

Therapeutic status for DM (n, %)

 Diet and exercise

342 (18.4)

76 (18.1)

0.880

–

–

–

 Antidiabetic agents

836 (44.9)

209 (49.6)

0.078

–

–

–

 Insulin

494 (26.5)

104 (24.7)

0.441

–

–

–

 Insulin and antidiabetic agents

190 (10.2)

32 (7.6)

0.104

–

–

–

  1. DM diabetes mellitus, BP-DES biodegradable polymer drug-eluting stents, G2-DES second generation drug-eluting stents, BMI body mass index, LVEF left ventricular ejection fraction, PAD peripheral arterial disease, COPD chronic obstructive pulmonary disease, OMI old myocardial infarction, PCI percutaneous coronary intervention, CABG coronary artery bypass grafting, NSTE-ACS non-ST-segment elevation acute coronary syndrome, STEMI ST-segment elevation myocardial infarction, DAPT dual antiplatelet treatment, GP glycoprotein, PPI proton pump inhibitors